XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenues - (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
March 31,
20242023
Xywav$315,300 $277,761 
Xyrem64,232 178,130 
Epidiolex/Epidyolex198,716 188,909 
Sativex2,735 7,098 
Total Neuroscience580,983 651,898 
Rylaze/Enrylaze102,750 85,927 
Zepzelca75,100 67,181 
Defitelio/defibrotide 47,676 39,079 
Vyxeos32,023 36,700 
Total Oncology257,549 228,887 
Other3,570 3,434 
Product sales, net842,102 884,219 
High-sodium oxybate AG royalty revenue49,947 2,096 
Other royalty and contract revenues9,934 6,497 
Total revenues$901,983 $892,812 

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
March 31,
20242023
United States$808,214 $810,116 
Europe71,355 65,900 
All other22,414 16,796 
Total revenues$901,983 $892,812 
Schedule of Revenues from Customers Representing More Than 10% of Total Revenues
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
March 31,
20242023
ESSDS42 %51 %
McKesson12 %12 %
Cardinal Health, Inc.8 %10 %